OrderlyMeds Review

What OrderlyMeds charges

• Semaglutide: $74 — presented as $74 a month but billed $149 for two months, to new customers only
• Semaglutide: $149/mo — per month "for those currently taking a GLP-1 medication, and for returning customers"
• Tirzepatide: $299/mo — per month; a new-customer starter is billed $299 for two months, presented as $149 a month
• NAD+: $224/mo — per month; a $448 lane exists but is gated to existing GLP-1 customers
• Sermorelin: $200/mo — per month; a $400 lane exists but is gated to existing GLP-1 customers

The letter names this seller's own website

A warning letter issued in June 2026 is attached to this record on the entity, not on a resemblance of names.

Its opening cites orderlymeds.com as the content reviewed, and its recipient block reads OrderlyMeds LLC dba OrderlyMeds at an address in Decatur, Georgia, with a support address at the same domain.

That is the seller's own letter. It is separate from anything that attaches to the pharmacies it names, which are different companies.

One of the pharmacies it names has its own enforcement record

ProRx LLC appears in the live federal warning-letter table twice, in April 2026 and in March 2025, both under the subject Compounding Pharmacy and Adulterated Drug Products.

Those two letters were issued to ProRx LLC. They are the pharmacy's, not OrderlyMeds', and nothing in them is an enforcement action against the seller.

The reason it matters to a buyer here is that OrderlyMeds names ProRx as one of the pharmacies that may fill the prescription, so a reader choosing this seller may end up with that dispenser.

Its own pages disagree about how many pharmacies there are

Its FAQ says "We currently partner with PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub and SmartPharmaRx".

Its home page names only three of those five. Both rosters are recorded and neither is treated as the correct one.

Its treatment pages compound the problem in a second way: branded-pen prices that are attributed correctly on its pricing page reappear there under bare molecule labels, which reads as though a compounded product costs what a branded pen costs.

What it says plainly, and what it will not say

In its own words its pharmacy partners are "503A designated" traditional compounding pharmacies that "must adhere to USP standards", and "Compounded drugs are not FDA-approved."

It states without hedging that it "does not require bloodwork for prescribing our medications", and sells at-home test kits as separate third-party goods rather than folding labs into the fee.

Its fifty-state line is about clinician licensure rather than shipping, and no state list is published, so no coverage claim is credited here. Its cheaper longevity lane is gated to existing weight-loss customers and is not treated as a general price.

FDA disclosure

OrderlyMeds received an FDA warning letter issued June 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Read the FAQ pharmacy roster and the home page roster separately and recorded both counts rather than reconciling them.
• Screened each named pharmacy as its own entity in the federal table, and recorded the two ProRx LLC letters against ProRx LLC rather than against this seller.
• Took the branded-pen attribution from the pricing page, where the brand names are printed, and declined the treatment pages' bare molecule labels for the same figures.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Confirmed the June 2026 warning letter belongs to this seller from the letter's own opening line, which names the seller's website, and from a recipient block carrying its company name, its Decatur address and its support address.